This week in FridayScience: A breakthrough in cancer treatment emerges – ONCOTECH. This novel therapy approach merges oncolytic virotherapy and adoptive TCell therapy, synergizing their strengths against cancerous tumors.
By attaching oncolytic viruses to T cells and targeting the PD-L1 gene, ONCOTECH promotes oncolysis, while T cells trigger cytotoxic effects, enhancing antitumor immunity and reducing tumor size for improved therapeutic outcomes.
As seen in a study published in Nature Portfolio, successful trials in various cancer models hint at a promising future of ONCOTECH for combating cancer.
